Skip to main content
SpringerLink
Log in

Efficacies and Chemical Structures of Modern Drugs for Hepatitis C Virus Treatment

  • Published:
Pharmaceutical Chemistry Journal Aims and scope

Hepatitis C virus (HCV) is the leading cause of chronic liver disease, surpassing hepatitis B virus and alcohol. The paradigm for treating HCV has radically changed over the last 20 years. The tolerability and duration of treating HCV patients was altered fundamentally by the emergence of modern and more efficacious treatment regimens and plans. Nevertheless, the risk of developing serious adverse reactions, including those due to drug–drug interactions, remains high. Currently, eight drugs are approved for treating HCV and avoid the use of interferons. The present article reviews these drugs with respect to their efficacy and safety for use in patients with various HCV genotypes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Global Hepatitis Report 2017, World Health Organization, Geneva (2017); http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1 (accessed Feb. 19, 2018).

  2. A. I. Gubenko and N. N. Eremenko, Vedom. Nauchn. Tsentra Ekspertizy Sredstv Med. Primeneniya, No. 4, 22 – 25 (2013).

  3. A. Binkley and N. S. Pandit, Pharmacy Times, July (2017); http://www.pharmacytimes.com/publications/issue/2017/july2017/hepatitis-c-treatment (accessed Feb. 19, 2018).

  4. I. I. Snegireva, E. Yu. Pasternak, K. E. Zatolochina, et al., Besop. Risk Farmakoter., 5(4), 161 – 169 (2017).

    Google Scholar 

  5. N. Tikhonova, T. Lopatkina, and A. Odintsov, Vrach, No. 8, 30 – 33 (2013).

  6. A. V. Vedernikova, M. V. Maevskaya, V. T. Ivashkin, et al., Ross. Zh. Gastroenterol., Gepatol., Koloproktol., 17(2), 40 – 49 (2007).

    Google Scholar 

  7. N. D. Yushchuk, O. O. Znoiko, K. R. Dudina, et al., Ter. Arkh., 88(6), 101 – 105 (2016).

    Article  CAS  PubMed  Google Scholar 

  8. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C, American Association for the Study of Liver Diseases, Infectious Diseases Society of America; hcvguidelines.org (accessed Feb. 19, 2018).

  9. A. S. Kazakov, R. N. Alyautdin, I. I. Snegireva, et al., Eksp. Klin. Farmakol., 80(3), 36 – 39 (2017).

    CAS  Google Scholar 

  10. J. L. Horsley-Silva and H. E. Vargas, Gastroenterol. Hepatol., 13(1), 22 – 31 (2017).

    Google Scholar 

  11. S. Zeuzem, M. Mizokami, S. Pianko, et al., J. Hepatol., 66(5), 910 – 918 (2017).

    Article  CAS  PubMed  Google Scholar 

  12. J. L. Romine, ACS Med. Chem. Lett., 2(3), 224 – 229 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. A. P. Rote, J. Alhat, and A. A. Kulkarni, Int. J. Pharm. Sci. Drug Res., 9(6), 291 – 298 (2017).

    Google Scholar 

  14. J. J. Feld, I. M. Jacobson, C. Hezode, et al., N. Engl. J. Med., 373(27), 2599 – 2607 (2015).

    Article  CAS  PubMed  Google Scholar 

  15. G. R. Foster, E. Gane, A. Asatryan, et al., J. Hepatol., 66, No. 1, S33 (2017).

    Article  Google Scholar 

  16. J. J. Kohler, J. H. Nettles, F. Amblard, et al., Infect. Drug Resist., No. 7, 41 – 56 (2014).

  17. J. J. Feld, K. V. Kowdley, E. Coakley, et al., N. Engl. J. Med., 370, 1594 – 1603 (2014).

    Article  CAS  PubMed  Google Scholar 

  18. A. Abergel, T. Asselah, S. Metivier, et al., Lancet Infect. Dis., 16(4), 459 – 464 (2016).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation, 8/2 Petrovskii Blvd, Moscow, 127051, Russia

    A. S. Kazakov, V. K. Lepakhin, T. M. Bukatina & I. I. Snegireva

  2. Peoples Friendship University of Russia, Moscow, 117198, Russia

    K. É. Zatolochina

Authors
  1. A. S. Kazakov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. K. Lepakhin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. M. Bukatina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. I. Snegireva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. É. Zatolochina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. S. Kazakov.

Additional information

Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 52, No. 6, pp. 9 – 12, June, 2018.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kazakov, A.S., Lepakhin, V.K., Bukatina, T.M. et al. Efficacies and Chemical Structures of Modern Drugs for Hepatitis C Virus Treatment. Pharm Chem J 52, 497–500 (2018). https://doi.org/10.1007/s11094-018-1847-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11094-018-1847-9

Keywords

Search

Navigation